Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 480 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Multiple Sclerosis (MS) Clear all
Completed Phase 1 Interventional

Open-label Study of Liothyronine in MS

NCT02506751
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
Interventions
liothyronine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 58 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 11, 2018 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Not applicable Interventional

Examining the Effects of a Remotely-delivered, Racially-tailored Exercise Training Program for Immediate and Sustained Improvements in Walking Dysfunction, Symptoms, and Health-related Quality of Life (HRQOL) Among African-Americans With Multiple Sclerosis (MS) Residing in Rural Environments.

NCT05516537
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Guidelines for Exercise in Multiple Sclerosis (GEMS), FLEX Stretching and Toning Program
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 22, 2026, 10:45 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)

NCT03222973
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
BIIB033 (opicinumab), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 58 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
51
States / cities
Cullman, Alabama • Gilbert, Arizona • Berkeley, California + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Jul 22, 2026, 10:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Observational Study to Establish Patient-Matched Population Norms for the Multiple Sclerosis Cognition Assessment Battery

NCT02283918
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
25 Years to 58 Years
Enrollment
467 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
4
States / cities
Thornton, Colorado • Decatur, Georgia • Latham, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2015 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

NCT03737851
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
elezanumab, placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Jul 22, 2026, 10:45 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS

NCT02446886
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®)
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Not applicable Interventional

Melatonin for Sleep in MS

NCT04035889
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Melatonin, Placebo
Dietary Supplement
Lead sponsor
University of California, San Francisco
Other
Eligibility
20 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 18, 2021 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Not applicable Interventional

Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis

NCT01848327
View directory record Official record
Conditions
Relapsing Remitting MS, Secondary Progressive MS, Primary Progressive MS
Interventions
Caprylic Triglyceride, Placebo
Dietary Supplement
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 59 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Jul 22, 2026, 10:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Role of Serum Leptin Levels in Multiple Sclerosis Disease Activity While on Interferon Beta 1a (Rebif) Treatment

NCT01067573
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 17, 2012 · Synced Jul 22, 2026, 10:45 AM EDT
Recruiting Not applicable Interventional

Blood Flow Restriction And Veterans With MS

NCT05433103
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Low-Load Exercise with Blood Flow Restriction, Low-Load Exercise Control Group
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jul 22, 2026, 10:45 AM EDT
Completed No phase listed Observational

Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron

NCT00461396
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions
Interferon-1beta (Betaseron, BAY86-5046)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 50 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Many Locations, Alabama • Many Locations, Arizona • Many Locations, Delaware + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2011 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2

NCT03093324
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
ALKS 8700, Dimethyl Fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
57
States / cities
Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Jul 22, 2026, 10:45 AM EDT
Completed No phase listed Observational

Evaluation of Natalizumab for thE Relief of MS Associated FatiGue

NCT00464074
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
30
States / cities
Phoenix, Arizona • Fresno, California • Atlanta, Georgia + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Not applicable Interventional

Computerized Cognitive Training in MS

NCT03737825
View directory record Official record
Conditions
Multiple Sclerosis, Cognitive Decline
Interventions
Computerized gaming rehabilitation Program 1, Computerized gaming rehabilitation Program 2
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 60 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jul 22, 2026, 10:45 AM EDT
Completed No phase listed Observational

A Therapeutic Experience Program (TEP) Study for Improvement of Gait in People With Multiple Sclerosis (MS)

NCT05437276
View directory record Official record
Conditions
Gait Impairment Due to Mild/Moderate Multiple Sclerosis (MS)
Interventions
PoNS®
Device
Lead sponsor
Helius Medical Inc
Industry
Eligibility
22 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
Atlanta, Georgia • Boston, Massachusetts • Foxborough, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Jul 22, 2026, 10:45 AM EDT
Completed No phase listed Observational

Ocrelizumab Effects on the Metabolome in MS

NCT03873389
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ocrelizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Jul 22, 2026, 10:45 AM EDT
Recruiting Not applicable Interventional

Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS

NCT04855825
View directory record Official record
Conditions
Multiple Sclerosis, Gait Disorders, Neurologic, Motility Disorder, Cognitive Impairment
Interventions
Robotic Exoskeleton Rehabilitation, Conventional Gait Therapy
Device · Other
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Jul 22, 2026, 10:45 AM EDT
Completed No phase listed Observational

A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis

NCT01541618
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
MSDX Complex-1 Biomarker test
Other
Lead sponsor
MSDx, Inc.
Industry
Eligibility
45 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis

NCT00879658
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
BAF312, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
16
States / cities
Cullman, Alabama • San Francisco, California • Centennial, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.

NCT05084638
View directory record Official record
Conditions
Relapse Remitting Multiple Sclerosis
Interventions
Ofatumumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 35 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
35
States / cities
Chandler, Arizona • Phoenix, Arizona • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Not applicable Interventional

Effect of Guided Imagery on Well-being in Patients With Multiple Sclerosis

NCT03177655
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
Guided Imagery, Journaling
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Jul 22, 2026, 10:45 AM EDT
Recruiting Not applicable Interventional

A Palliative Care Model Impact on Knowledge and Attitudes

NCT06860932
View directory record Official record
Conditions
Multiple Sclerosis, MS
Interventions
Palliative care video comprises the conversation and advance directives., Palliative care written material
Behavioral
Lead sponsor
Hunter College of City University of New York
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 22, 2026, 10:45 AM EDT
Completed No phase listed Observational

Utilization of the Ketogenic Diet in Patient With Relapsing Remitting MS

NCT03718247
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Modified Atkins diet
Other
Lead sponsor
University of Virginia
Other
Eligibility
12 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Restoration of Walking in Multiple Sclerosis Using Treadmill Training.

NCT00156676
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Body-weight supported treadmill, Lokomat
Device
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Jul 22, 2026, 10:45 AM EDT